Emergent Biosolutions Inc

Healthcare · Drug Manufacturers - Specialty & Generic

6.80$ -3.1% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Balance Sheet

Emergent Biosolutions Inc (EBS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 1,319 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet EBS
Line item	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	25	23	–	69	100	238	274	291	345	500	547	564	627	945	1,044	970	1,070	2,229	2,327	2,883	2,958	3,166	1,823	1,390	1,319
Current Assets	1,196	4.9	–	42	59	147	144	153	194	243	254	263	273	432	539	510	485	621	686	1,196	1,270	1,210	680	599	663
Cash	5.9	4.9	–	6.8	36	76	106	91	103	169	144	142	179	280	313	272	178	112	168	621	576	643	112	100	205
Cash & Short-Term Investments	5.9	4.9	–	6.8	36	76	106	91	103	171	146	142	179	280	313	272	178	112	168	621	576	643	112	100	205
Receivables	231	–	–	19	3.3	44	19	25	67	48	84	96	66	60	127	148	146	263	275	231	279	159	191	155	84
Inventory	307	–	–	13	16	25	17	20	14	13	15	15	15	66	77	74	143	206	223	307	345	351	329	312	343
Property, Plant & Equipment	–	–	–	27	31	78	110	125	132	153	209	242	264	314	332	376	407	510	542	644	800	818	399	282	216
Goodwill	267	–	–	–	–	–	–	–	–	5.0	5.5	5.5	14	42	55	41	49	260	267	267	225	218	218	–	–
Intangible Assets	663	–	–	–	–	–	–	–	–	51	51	42	72	136	100	34	120	812	742	663	605	729	567	502	437
Total Liabilities	58	19	–	46	41	100	102	91	101	127	130	122	137	392	384	374	158	1,219	1,239	1,436	1,346	1,779	1,174	907	796
Current Liabilities	385	–	–	34	30	64	56	54	55	76	71	62	57	93	100	106	100	200	216	385	374	1,229	651	162	132
Short-Term Debt	34	–	–	1.0	1.4	11	15	21	21	17	5.4	4.5	26	40	43	20	43	10	16	45	37	963	414	2.7	0.0
Accounts Payable	136	–	–	5.5	10	27	18	18	17	25	41	31	28	41	46	35	42	81	95	136	129	104	112	61	56
Long-Term Debt	–	–	–	12	11	31	43	36	45	30	54	58	62	251	253	248	13	785	798	841	809	449	447	664	572
Shareholders' Equity	-32	4.2	–	23	60	138	171	199	241	369	414	441	489	553	660	596	912	1,011	1,089	1,447	1,612	1,388	649	483	523
Retained Earnings	727	–	–	15	25	48	70	91	122	174	197	220	252	288	351	254	337	367	422	727	950	739	-22	-212	-160
Shares Outstanding	18	21	20	20	23	25	30	30	31	33	36	36	37	46	47	49	50	51	52	54	54	50	51	53	57

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings